Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD3199 Turbuhaler · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dry powder for oral inhalation |
| 2 | PLACEBO_COMPARATOR | Dry powder for oral inhalation |
| Name | Type | Description |
|---|---|---|
| AZD3199 Turbuhaler® | DRUG | 240, 720 and 2160 μ g, single and multiple (o.d. for 12 days) |
| Placebo Turbuhaler® | DRUG | single and multiple (o.d. for 12 days) |
Inclusion Criteria: * Be healthy Japanese volunteers, both of the volunteer's parents, and all grandparents must be Japanese. The volunteer must have been born in Japan, have a valid Japanese passport and must not have lived outside Japan for for more than 5 years. * BMI 18 - 27, Weight 50 - 85 kg ...
AZD3199 Turbuhaler is an investigational small molecule drug developed by AstraZeneca PLC (ticker AZN). It is delivered through a Turbuhaler device and has been studied in a Phase 1 clinical trial in healthy volunteers. Its therapeutic indication has not been disclosed.
AZD3199 Turbuhaler targets ADRB2, the beta-2 adrenergic receptor, and acts as an agonist at that receptor. This target class places it among beta-2 adrenergic receptor agonists, a group commonly explored for airway-related conditions.
AZD3199 Turbuhaler is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program for this investigational compound.
AZD3199 Turbuhaler is in Phase 1 development. It is an investigational drug and is not approved; the only recorded trial is a completed Phase 1 study. No active trials are currently listed for this asset.
AZD3199 Turbuhaler has been evaluated in one clinical trial, NCT00772759, titled "Assess Safety, Tolerability and PK of AZD3199 in Japanese." That Phase 1 study was completed, enrolled 27 healthy male participants, was randomized, double-blind, and placebo-controlled, and was conducted in the United Kingdom.
Yes. AZD3199 Turbuhaler and AZD3199 Turbuhaler® refer to the same investigational drug from AstraZeneca. The registered trademark symbol is simply a naming variant, so searches using either form point to the same compound and the same clinical program.